(☞゚∀゚)☞♡ try KnowYourSong.com largest music lyrics database

Dr. West on FDA Approval of Brigatinib in ALK+ NSCLC

Say and pronounce Dr. West On on SuperTTS.com Make Your Own Text-To-Speech Words Instantly

  Info

Description

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the FDA approval of brigatinib (Alunbrig) as a treatment for patients with metastatic ALK-positive non–small cell lung cancer (NSCLC) who are resistant to prior crizotinib (Xalkori).

Tags

cancer oncology
  Email Video to Friends   Receive Emails for Similar Videos

Email:

  Repeat and Loop Video   Link to Video   Create Short URL  Publish Text About This Video   Share on Facebook, Twitter, and more
  See Recommended Videos For You
Old Cartoons on DVD. Visit and Bookmark: Cool90s.com!

Related

  FDA Approval of Brigatinib for ALK+ NSCLC   Dr. West on FDA Approval of Frontline Alectinib in ALK+ NSCLC   Evolving Approaches for Treating ALK-Positive NSCLC   FDA Approval: Frontline Ceritinib for ALK+ NSCLC   ALTA II Trial of Brigatinib in ALK-Rearranged NSCLC   Dr. Neal Debates Whether Alectinib Will Become the Standard Frontline Thera for ALK+ NSCLC   Dr. Wakelee on FDA Approval of Frontline Pembrolizumab in NSCLC   FDA Approval in Carcinoid Syndrome Diarrhea, Priority Reviews in Bladder Cancer and NSCLC, and More   Dr. Spigel on FDA Approval of Pembrolizumab/Chemo Combo in NSCLC   Emerging ALK/ROS1 TKIs for NSCLC   Next-Generation ALK Inhibitors for NSCLC   FDA Approval of Atezolizumab for NSCLC   Dr. Villaflor Discusses Alectinib in ALK+ NSCLC   Progression of ALK+ NSCLC   Dr. Gandhi on Sequencing and Emerging Agents in ALK+ NSCLC   Dr. Gandhi on Pembrolizumab/Chemo Findings in NSCLC and FDA Approval   Treatment of Relapsed/Refractory ALK+ NSCLC   Dr. Brammer on FDA Approval of Brentuximab Vedotin in CTCL   ALK Inhibitor Sequencing in NSCLC   Sequencing Therapies in ALK+ NSCLC   Dr. Garcia on FDA Approval of Pembrolizumab in Bladder Cancer   Dr. Mok on Breakthrough Therapies for ALK-Positive NSCLC   Dr. Bendell on FDA Approval of Regorafenib in Liver Cancer   Dr. Al-Kali on FDA Approval of Enasidenib in AML   Dr. Straus on FDA Approval of Pembrolizumab in Hodgkin Lymphoma   Review on 2016 FDA Approvals, Halt on AML Trials, and More   Development of ALK-Targeted Therapy for NSCLC   Dr. Velcheti on Potential of Alectinib in Frontline ALK-Positive NSCLC   Dr. Gubens on Prevalence of EGFR/ALK/ROS1 and PD-L1 Expression in NSCLC   Crizotinib for ALK-Rearranged NSCLC   Breakthrough In Leukemia Treatment   EGFR & ALK/ROS1 Testing in Squamous NSCLC   Ceritinib and Alectinib in Relapsed ALK+ NSCLC   New drug trial heals dogs of arthritis   Treatment of ALK-Driven Refractory NSCLC   Clarence-based company could become first to sell very low nicotine cigarette   Future Directions for ALK+ NSCLC   Next-Generation ALK-Targeted Agents in NSCLC   Upfront Use of Second-Generation TKIs in ALK+ NSCLC   Dr. Shaw on the Phase III Results of the ALEX Trial in NSCLC   Upfront Use of Next-Generation ALK Inhibitors in NSCLC   The Evolution of ALK/ROS1-Targeted Therapy in NSCLC   Upfront Use of Second-Line Agents in ALK+ NSCLC   Extended Cut: Should the Terminally Ill Have the Right to Try, Non FDA Approved Drugs?   Durvalumab FDA Approval for Bladder Cancer   Patterns of Progression on Crizotinib for ALK+ NSCLC   Alectinib for Relapsed/Refractory ALK+ NSCLC   The FDA Approval of Atezolizumab in Bladder Cancer   New cancer treatment offers patients hope   Novartis Metastatic Breast Cancer Treatment   Cancer Advance of the Year, FDA Approval for CINV, Breakthrough Designation in TNBC, And More   Experience with Ceritinib for ALK+ NSCLC   Choosing Second-Line Therapy for ALK+ NSCLC   Next Generation ALK Inhibitors for NSCLC   Ceritinib Alternative Dosing for ALK+ NSCLC   Third-Generation ALK Inhibitors for NSCLC   FDA Approval in AML, Priority Review Designation in NSCLC, and More   FDA Approval in MZL, Delay in Immunotherapy Combos in NSCLC, and 2017 GI Symposium Highlights   FDA Approval in CLL, Recommendation in NSCLC, Missed Endpoint in GBM Study, and More   FDA Approval and Priority Review in Ovarian Cancer, End of Part B Payment Model, and More   FDA Approval in Lung Cancer, Priority Reviews in HCC and NHL, and an ODAC Recommendation   21st Century Cures Act Passes and 2016 Highlights from SABCS and WCLC   Dr. McKay on FDA Approval of Nivolumab/Ipilimumab in Frontline RCC   Dr. Grothey on FDA Approval of Pembrolizumab in MSI-High CRC   Dr. Siefker-Radtke on FDA Approval of Frontline Atezolizumab in Bladder Cancer   FDA Approval and 2 Priority Reviews in Bladder Cancer, and ASCO's Cancer Advance of the Year   Plasma Testing for NSCLC EGFR & ALK Mutations   Dr. Kelly on the FDA Approval of Ribociclib in HR+ Breast Cancer   Dr. Steinberg on the FDA Approval of Atezolizumab in Bladder Cancer   Dr. Siefker-Radtke on FDA Approval of Durvalumab in Bladder Cancer   Dr. Erba on the FDA Approval of CPX-351 in AML   Buffalo first city in U.S. to use new ALS drug   FDA Approval of Durvalumab for Bladder Cancer   Nivolumab Lung Cancer Approval Expanded, Abemaciclib Granted Breakthrough Status, and More   How Does The FDA Approve New Drugs?

Popular Today